therapeutics

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response…

5 months ago

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress

October 19, 2025 10:00 ET  | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…

5 months ago

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

October 19, 2025 08:00 ET  | Source: RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) --…

5 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

October 14, 2025 08:05 ET  | Source: Candel Therapeutics NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.…

6 months ago

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

-   Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET -   Poster presentation on preclinical evaluation of petosemtamab…

6 months ago

Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company…

6 months ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares for Gross Proceeds of $345 Million

SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

6 months ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025 16:05 ET  | Source: Vera Therapeutics BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc.…

6 months ago

Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma

October 09, 2025 02:00 ET  | Source: Ariceum Therapeutics Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study…

6 months ago

Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International Markets

New CSO & GM role underscores Halia's commitment to resilience-based therapeutic development and advances collaboration with the Department of Health…

6 months ago